Impacts of off-label dosing noacs on clinical outcomes in very elderly patients with atrial fibrillation

被引：0
|
作者：
Chao, T. [1 ]
Chan, Y. H. [2 ]
Lip, G. Y. H. [3 ]
Chen, S. A. [4 ]
机构：
[1] Taipei Vet Gen Hosp, Taipei, Taiwan
[2] Chang Gung Mem Hosp, Taoyuan, Taiwan
[3] Univ Liverpool, Liverpool, Merseyside, England
[4] Taichung Vet Gen Hosp, Taichung, Taiwan
来源：
EUROPEAN HEART JOURNAL | 2021年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：565 / 565
页数：1
相关论文
共 50 条
  • [21] Clinical features of very elderly cardloembolie patients with atrial fibrillation
    Hoshino, H.
    Takagi, M.
    Fujioka, S.
    CEREBROVASCULAR DISEASES, 2018, 45 : 439 - 439
  • [22] Reply: How to Demonstrate the Clinical Impact of Off-Label Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation
    Kino, Tabito
    Nogami, Akihiko
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2025,
  • [23] Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin
    Avendano, Ricardo
    Romero, Jorge
    Lupercio, Florentino
    Diaz, Juan Carlos
    Quispe, Renato
    Golive, Anjani
    Natale, Andrea
    Garcia, Mario J.
    Krumerman, Andrew K.
    Di Biase, Luigi
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2019, 54 (01) : 73 - 80
  • [24] Characteristics and Outcomes in Patients With Atrial Fibrillation (af) Receiving Direct Oral Anticoagulants (doacs) in off-Label Dose.
    Sarrazin, Vaughan Mary S.
    Briasoulis, Alexandros
    Leira, Enrique C.
    STROKE, 2019, 50
  • [25] OFF-LABEL USE OF NEW ORAL ANTICOAGULANTS IN ABLATION FOR ATRIAL FIBRILLATION
    Rodriguez, A. V.
    Andres, A. L.
    Villuendas, R.
    Montane, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 34 - 34
  • [26] Patient Characteristics and Predictors of Off-Label versus Standard Dosing of Direct Oral Anticoagulants in Medicare Beneficiaries With Atrial Fibrillation
    Briasoulis, Alexandros
    Gao Yubo
    Vaughan Sarrazin, Mary
    CIRCULATION, 2018, 138
  • [27] Impact of real-world off-label dose of apixaban on long-term clinical outcomes in patients with atrial fibrillation and chronic kidney disease
    Shin, Ho Sik
    Kil, Song Yi
    Park, Byung Hwa
    Kim, Ye Na
    Jung, Yeonsoon
    Rim, Hark
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I924 - I924
  • [28] Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation
    Lee, So-Ryoung
    Choi, Eue-Keun
    Park, Sang-Hyun
    Jung, Jin-Hyung
    Han, Kyung-Do
    Oh, Seil
    Lip, Gregory Y. H.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (05) : 415 - 423
  • [29] Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis
    Joosten, Linda P. T.
    van Maanen, Rosanne
    van den Dries, Carline J.
    Rutten, Frans H.
    Hoes, Arno W.
    Granger, Christopher B.
    Hemels, Martin E. W.
    Geersing, Geert-Jan
    van Doorn, Sander
    OPEN HEART, 2023, 10 (01):
  • [30] Clinical Outcomes of Surgical Ablation of Atrial Fibrillation in Elderly Patients
    Soni, Lori K.
    Lippel, Matthew
    Hwang, Lewis C.
    Yang, Jonathan A.
    Yang, Jonathan A.
    Chan, Edward Y.
    Cheema, Faisal H.
    Argenziano, Michael
    CIRCULATION, 2011, 124 (21)
12345